Key Inclusion Criteria
  -  Male or female subjects ≥ 12 to < 18 years of age
  -  Chronic AD that has been documented for at least 2 years
  -  Eczema Area and Severity Index (EASI) score ≥ 16
  -  IGA score ≥ 3
  -  AD involvement ≥ 10% of Body Surface Area (BSA)
  -  Documented recent history of inadequate response to topical medications
  -  Women of childbearing potential must agree to be strictly abstinent or to use an effective and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.
Key Exclusion Criteria
  -  Body weight < 30 kg
  -  Cutaneous infection within 1 week or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week
  -  History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody)
  -  Any clinically significant issue, based investigator judgement